Sandra P. D’Angelo

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor et al. · The Lancet Oncology · 2015 · 2.7K citations

Medicine, Oncology, Pharmacotherapy +16

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

Sandra P. D’Angelo, James Larkin, Jeffrey A. Sosman et al. · Journal of Clinical Oncology · 2017 · 643 citations · Full text

Medicine, Immunology, Oncology +17

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

James Larkin, David R. Minor, Sandra P. D’Angelo et al. · Journal of Clinical Oncology · 2017 · 510 citations · Full text

Medicine, Oncology, Pharmacology +17

De Novo Synthesis of Cyclooxygenase-1 Counteracts the Suppression of Platelet Thromboxane Biosynthesis by Aspirin

Virgilio Evangelista, Stefano Manarini, Angelo Di Santo et al. · Circulation Research · 2006 · 124 citations · Full text

Medicine, Cardiology, Pharmacology +17

A Phase 3 Randomized, Open-Label Study of Nivolumab (Anti-Pd-1; Bms-936558; Ono-4538) Versus Investigator'S Choice Chemotherapy (Icc) in Patients with Advanced Melanoma After Prior Anti-Ctla-4 Therapy

Jeffrey S. Weber, David R. Minor, Sandra P. D’Angelo et al. · Annals of Oncology · 2014 · 71 citations · Full text

Medicine, Immunology, Oncology +14